Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 41, Issue 7, 2008, Pages 613-619

  Benekli, M ^a   Smiley, S L ^b   Younis, T ^b   Czuczman, M S ^b   Hernandez Ilizaliturri, F ^b   Bambach, B ^b   Battiwalla, M ^b   Padmanabhan, S ^b   McCarthy Jr , P L ^b   Hahn, T ^b  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLADDER DISEASE; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INCIDENCE; INFECTION COMPLICATION; INTERSTITIAL PNEUMONIA; KARNOFSKY PERFORMANCE STATUS; LIVER TOXICITY; LUNG FIBROSIS; LUNG TOXICITY; MALE; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; STOMATITIS; SUBDURAL HEMATOMA; SURVIVAL RATE; SURVIVAL TIME; TRANSBRONCHIAL BIOPSY; TREATMENT RESPONSE; VEIN OCCLUSION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT FAILURE;

EID: 42149184655     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705951     Document Type: Article

References (45)

1. Aisenberg AC. Problems in Hodgkin's disease management. Blood 1999; 93: 761-779.
2. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15: 528-534.
3. Fung HC, Nademance AP. Approach to Hodgkin's lymphoma in the new millennium. Hematol Oncol 2002; 20: 1-15.
4. Longo DL, Glatstein E, Duffey PL, Young RC, Ihde DC, Bastian AW et al Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. J Clin Oncol 1997; 15: 3338-3346.
5. Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol 1999; 17: 222-229.
6. Anselmo AP, Meloni G, Cavalieri E, Proia A, Enrici RM, Funaro D et al Conventional salvage chemotherapy vs high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patienst. Ann Hematol 2000; 79: 79-82.
7. Bierman PJ, Bagin RG, Jagannath S, Vose JM, Spitzer G, Kessinger A et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long-term follow-up in 128 patients. Ann Oncol 1993; 4: 767-773.
8. Horning SJ, Chao NJ, Negrin RS, Hoppe, RT, Long GD, Hu WW et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801-813.
9. Lazarus HM, Loberiza Jr FR, Zhang MJ, Armitage JO, Ballen KK, Bashey A et al. Autotransplants for Hodgkin's disease in first relapse or second remission: A report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 2001; 27 387-396.
10. Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ et al. Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999; 17: 534-545.
11. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
12. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124: 645-652.
13. Nademanee,A, O'Donnell MR, Snyder DS, Schmidt GM, Parker PM, Stein AS et al. High-dose chemotherapy with or without total body. irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood 1995; 85: 1381-1390.
14. Rapoport AP, Rowe JM, Kouides PA, Duerst RA, Abboud CN, Liesveld JL et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11: 2351-2361.
15. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, Garcia-Conde J et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395-1404.
16. Sweetenham JW, Taghipour G, Milligan D, Blystad AK, Caballero D, Fassas A et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 745-752.
17. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814-822.
18. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E et al Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 1992; 10: 210-218.
19. Hahn T, Benekli M, Wong C, Moysich KB, Hyland A, Michalek AM et al A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant 2005; 35: 557-566.
20. Phillips GL, Wolff SN, Herzig RH, Lazarus HM, Fay JW, Lin HS et al Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 1989; 73: 2086-2092.
21. Stiff PJ, Unger JM, Forman SJ, McCall AR, LeBlanc M, Nademanee AP et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease:. a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003; 9: 529-539.
22. Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma, autografted after a first relapse. Ann Oncol 2005; 16: 625-633.
23. Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M et al High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: A prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997; 3: 98-106.
24. Bolwell BJ, Kalaycio M, Goormastic M, Dannley R, Andresen SW, Lichtin A et al. Progressive disease after ABMT for Hodgkin's disease. Bone Marrow Transplant 1997; 20: 761-765.
25. Arranz R, tomas JF, Gil-Fernandez JJ, Martinez-Chamorro C, Granados E, Alegre A et al, Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): Comparative results with two CBV regimens and importance of disease status at transplant. Bone Marrow Transplant 1998; 21: 779-786.
26. Fleming DR, Wolff SN, Fay JW, Brown RA, Lynch JP, Bolwell BJ et al Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: A phase II study from the North American Marrow Transplant Group. Leuk Lymphoma 1999; 35: 91-98.
27. Reece DE, Barnett MJ, Connors JM, Fairey RN, Fay JW, Greer JP et al Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 9: 1871-1879.
28. Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ et al Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: A dose-finding study. J Clin Oncol 1990; 8: 648-656.
29. Bearman SI, Appelbaum RF, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1998; 6: 1562-1568.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
31. Bierman PJ, Anderson JR, Freeman MB, Vose JM, Kessinger A, Bishop-MR et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotheraphy. Ann Oncol 1996; 7: 151-156.
32. Crilley P, Lazarus H, Topolsky D, Ciobanu N, Creger RJ, Fox RM et al Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies. Semin Oncol 1993; 20: (Suppl 4): 50-54.
33. Kroger N, Hoffnecht M, Hanel M, Kruger W, Zeller W, Stockschalder M et al. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy: Bone Marrow Transplant 1998; 21: 1171-1175.
34. Lazarus HM, Crilley P, Ciobanu N, Creger RJ, Fox RM, Shina DC et al High dose carmustine, etoposide and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. J Clin Oncol 1992,10: 1682-1689.
35. Moskowitz CH, Nimer SD, Zelenetz AD, Tripett T, Hedrick EE, Filippa DA et al. A 2rstep comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616-623.
36. Evens AM, Altman JK, Mittal BB, Hou N, Rademaker A, Patton D et al Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Ann Oncol 2007; 118: 679-688.
37. Caballero MD, Rubio V, Rifon J, Heras I, Garcia-Sanz R, Vazquez L et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451-458.
38. Chopra R, Linch DC, McMillan AK, Blair S, Patterson KG, Moir D et al Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. Br J Haematol 1992; 81: 197-202.
39. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1991; 81: 1137-1145.
40. Geisler CH, Hansen MM, Andersen NS, Brown P, Christensen LD, Dickmeiss E et al. BEAM + autologous stem cell transplantation in malignant lymphoma: 100 consecutive transplants in a single center. Efficacy, toxicity and engraftment in relation to stem-cell source and previous treatment. Eur J Haematol 1998; 61: 173-182.
41. Smith AG, Long SG, Janmohammed RM, Macdonald DF, Leyland MJ, Milligan DW et al. BEAM autografting in lymphoma - experience at one centre. Leuk Lymphoma 1992; 7 (Suppl): 23-28.
42. Demirer T, Weaver CH, Buckner CD, Petersent FB, Bensinger WI, Sanders J et al. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. J Clin Oncol 1995; 13: 596-602.
43. Weaver CH, Appelbaum FR, Petersen FB, Clift R, Singer J, Press O et al. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 1993; 11: 1329-1335.
44. Jones RB, Matthes S, Kemme D, Dufton C, Kernan S. Cyclophosphamide, cisplatin, and carmustine: Pharmaco-kinetics of carmustine following multiple alkylating-agent interactions. Cancer Chemother Pharmacol 1994; 35: 59-63.
45. Jones RB, Matthes S, Shpall FJ, Fisher JH, Stemmer SM, Dufton C et al Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: Pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 1993; 85: 640-647.